IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
Review Article
May 2024 Vol.:30, Issue:5
© All rights are reserved by Manisha R. Mashalkar et al.

Electrospun Nanofiber Strategies for Diabetes Management

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Manisha R. Mashalkar[*1], Rajashri S. Biradar[2], Shivam S. Vyavahare [3] Rakhi N. Marashivane[4], Dr. Omprakash G. Bhusnure[5], Pragati B. Wattamwar[6]

[1,2,3,4] *M. Pharmacy Second Year Students, Channabasweshwar College (Degree) Latur - 413512, Maharashtra, India*

[5] *Professor & Research Director, Department of Pharmaceutical Quality Assurance, Channabasweshwar College (Degree) Latur - 413512, Maharashtra, India*

[6] *Assistant Professor, Department of Pharmaceutical Quality Assurance, Channabasweshwar College (Degree) Latur - 413512, Maharashtra, India*

Submitted: 24 April 2024
Accepted: 30 April 2024
Published: 30 May 2024

Keywords: Electrospinning, Nanofibers, Diabetes Management, Drug Delivery, Gliclazide, Antidiabetic Agents

ABSTRACT

Electrospun nanofibers offer promising strategies for diabetes management through their unique properties and versatile applications. These nanofibers are suitable for controlled drug delivery, promoting tissue regeneration, and wound healing, as well as creating glucose-responsive systems for diabetes monitoring and management. Their high surface area-to-volume ratio allows for enhanced drug loading capacity. Further research is essential to fully harness the potential of electrospun nanofibers in diabetes care.

HUMAN JOURNALS
ijppr.humanjournals.com

1. INTRODUCTION:

Nanotechnology, a promising 21st-century innovation, enables the observation, measurement, manipulation, assembly, and manufacturing of nanomaterials on a nanoscale. This technology finds novel applications in diverse fields such as chemistry, physics, biology, medicine, engineering, and electronics[3]. Nanotechnology requires two conditions: scale control and novelty in utilizing nanoscale structures and utilizing properties of small things. [4].

The interdisciplinary field of nanotechnology is concerned with the substantial enhancements and new modifications of materials' properties that result from their conjugation to nanoscale structures. [5]. A new generation of nonwoven fabric-based materials for practical applications in interdisciplinary research fields has been made possible by the creation of electrospun nanofibers [6,7,8,9]. The growing number of relevant electrospinning research publications indicates the development of purposeful research, the growth of electrospinning technology, and the creation of electrospun nanofibers. This survey covers all articles containing search terms related to electrospun nanofibers published in the period June 2021–2010. Web of Science internet search technology was used to support uantifiable information in the surveys for literary studies.

Electrospun nanofibers possess remarkable properties such as a high surface-to-volume ratio, lightweight structure, high tortuosity, high permeability, and an interconnected ultrafine fiber structure. These properties result from advanced electrospinning technology. Researchers from all over the world have been paying close attention to diameters of electrospun nanofibers as small as 100 nm, and they are prepared to shift towards an interdisciplinary approach based on practice in a number of domains [10,11,12,13, 14].

German creator Anton Formhals laid the groundwork for the growth of technology in electrospinning in the early 1930s with his revolutionary concept for creating synthetic fibers that resembled silk. Silk was a very popular pricey substance and upscale textile at the start in the 20th century. Finding a less expensive substitute material was therefore an intriguing endeavor, and Formhals was really the first to discover how to create threads in an electrical field originating from a dissolved solid. His 22 patents, which were linked to development of method of electrospinning, were unable to compete with the large-scale commercial fiber-spinning techniques of the previous decades, which caused a long-term delay in their future development [15]. Even though electrospinning is a rather old method, it has developed

quickly in recent years following the discovery late in the 1960s of the remarkable nanostructural properties of nanofibers created through electrospinning [16,17].

Currently, among the most popular techniques for creating one-dimensional (1D) polymer fiber nanostructures is electrospinning, which depends on a high voltage environment to create an interconnected fibrous web from solutions containing various polymers and polymer mixes. Because electrospun fiber production may be tailored into a variety of fiber morphologies, electrospinning is a highly adaptable technology. Electrospun nanofibers like this can be shaped into a variety of morphological shapes, including hollow core shells, porous structures, aligned or randomly oriented nanofiber meshes, and the integration of additional materials, depending on the specific copolymer used [18]. Because of the adaptability of electrospinning technology, a large selection of products made from nanofibers that can be tailored in terms of composition, size, and morphology to carry out a number of functions have been developed more quickly [19, 20, 21]. Figure 1 illustrates a schematic of an electrospinning machine. A suitable distance apart was maintained between a precision syringe pump, conductive collector, and high-voltage source in a normal laboratory electrospinning machine. Both the steadily positioned collector and every charged spinneret had the power supply connected to them.

High-voltage charges were applied to spinning solutions that were injected the metal ring and contained in the syringe. The liquid meniscus's pendant drop shape changes to a "Taylor cone" shape because of the electrical forces that are induced exceeding the charged liquid's surface tension. Before the ultrafine fibers the gatherer as electrospun fibers, they are created by the instability caused by whipping and twisting that happens when a charged liquid[22-25]. The mesh of nanofibers deposited is often gathered as sheets with a thickness of 10–30 mm after the electrospinning process, above a conductive substrate. Typically, the nanofiber mesh sheet needs to be taken off of the conductive substrate in order for it to be applied in its subsequent uses.

.



Figure 1. Schematic representation of a vertical electrospinning setup.

The increasing technological interest of electrospinning has made it possible for them to develop further since it allows for the controlled integration of nanoparticles into these filaments that are nanoscale by blending a polymer solution with the nanoparticles before the spinning process. Since nanofibers are easy to use, highly efficient, inexpensive, and highly reproducible, electrospinning has been recognized as a powerful method for creating fibrous structured materials at the nanoscale [26, 27]. According to previously published research, filtration, functional textiles, biomedical, and electrical devices were the main areas of interest for nanofiber applications [15, 28, 29, 30,]. Numerous study papers regarding the parameters of electrospinning, characterisation, and Electrospun nanofiber uses include published by researchers [18, 22, 26, 29, 31- 40].

Nevertheless, the fibers' commercialization and the resulting product based on their commercial nanofibers has not received much attention in previous studies. Therefore, the purpose of this paper is to provide a summary of the recent developments regarding the scalability of electrospun nanofiber manufacturing and the global selling of goods made from electrospun nanofibers by committed enterprises. This review's scope will include the most recent developments in the electrospinning process for manufacturing nanofiber fabrics, the difficulties in maintaining manufacturing scalability and quality control, the most recent research on products based a study on nanofibers prediction for the future of electrospun nanofibers. Prospective resources are also emphasized in the article under examination.

Fibers that are smaller than 50–500 nanometers in diameter are referred to as nanofibers. According to the National Science Foundation (NSF), nanofibers are defined as having at least one dimension that is 100 nanometers (nm) or smaller. Lately, drug delivery methods for a variety of disorders have employed nanofibers in the healthcare system. Applying nanofibers demonstrates their value and practicality as medication carriers. Their smaller size is crucial for getting the medication to the suitable place in the body.(41)

It has always been crucial to deliver medications or pharmacological agents to patients in a method that is most physiologically acceptable. Delivery systems for medications are made to accurately, efficiently, and for a predetermined amount of time provide a prescribed dose of medication. The delivery of medications will be significantly impacted by the new materials and technology. Drug release can be regulated by using biodegradable or non-biodegradable materials, and it can happen by diffusion just or diffusion plus scaffold breakdown.

Furthermore, a variety of medications, including antibiotics, anticancer drugs, proteins, and DNA, can be administered due to the versatility in material selection.A variety of drug loading approaches, including coatings, embedding drug, and encapsulated drug (coaxial and emulsion electrospinning), can also be employed with the diverse electro spinning procedures. The kinetics of medication release can be more precisely controlled with aid of these techniques(42).

2. ASPECTS OF NANOFIBERS

The primary reason why nanofibers have unique characteristics above traditional nonwovens is their incredibly high surface to weight ratio. The nanofiber nonwoven is suitable for a variety of filtration applications due to its narrow pore size, high pore volume, big surface area to mass, and low density.

1. Nanofibers can be made from a variety of polymers.
2. The range of its diameters is nanometers.
3. Covalent bonds are used to join polymer chains.
4. The type of polymer and the manner of manufacture affect the nanofibers' diameters.
5. A distinctive feature of a high volume to surface area ratio in nanofibers.
6. Its porosity is high.

7. Its mechanical strength is appropriate.

8. Excellent adaptability.

9. There are numerous technological and economic uses for nanofibers.

3. Applications for Nanofiber

1. Tissue engineering uses nanofibers.

2. Area of tissue engineering for bones, nanofiber scaffolds are utilized to replicate the extracellular matrix that naturally exists in bones.

3. One potential drug carrier choice is nanofibers.

4. The selection of a drug transporters has a major impact on the therapeutic's ability to reach its target.

5. After surgery, surfaces coated with nanofiber scaffolds can act as adhesion barriers separating internal organs from surrounding tissues.

6. The diagnosis of cancer uses nanofiber.

7. Lithium-air batteries are made with it.

8. The optical and electrical features of quantum dots, such as their robust photochemical stability and excellent optical gain, are beneficial.

9. Nano-fibers made of polymers have been effectively combined with a range of quantum dots. (43)

4. Diabetes and Nanotechnology

Nanoparticles (< 100 nm Dimensions) are used in nanotechnology. These nanoparticles are created by adjusting certain molecules or atoms within a material. Nanomedicine is the word used to describe using nanotechnology in the medical field. The area of nanomedicine combines the understanding of nanotechnology utilizing the implementation of pharmaceuticals or diagnostic compounds to enhance their ability to target particular cells or tissues. Through the application of cutting-edge nanotechnology-based glucose testing and insulin administration systems, diabetes research has utilized nanotechnology in several ways to improve the outcomes of diabetic treatment in diabetics [44, 45].

Non-invasive methods of delivering insulin and creating a more effective vaccination, such as gene- and cell-based treatments for type 1 diabetes, are made possible by nanotechnology [44]. Nanotechnology plays a important part in diabetes care through innovative diabetes diagnosis, immune cell activity and beta-cell mass detection, glucose monitoring, non-invasive insulin delivery, and more. It's possible that receiving an accurate and timely diagnosis of a disease is just as crucial as treating it. Early detection can delay the onset of diabetes and prevent dysglycemia [46]. Traditional methods have been applied to several diabetes diagnostic requirements, including measuring plasma glucose levels and/or identifying immunological damage prior to T1DM. Nonetheless, a revolutionary technique that can enhance the diagnostic outcome is required due to the drawbacks of the conventional methodologies, which include, but are not limited to, the inability to detect the illness progression at an early stage.

The mass of the beta cell provides information about how well it functions in secreting insulin. T1DM is brought on by the gradual depletion of beta cells [47]. Using nanotechnology to quickly identify the stage of beta cell loss can enable the rapid administration of therapeutic measures to stop it. For the magnetic resonance imaging (MRI), magnetic nanoparticles (MNPs) are an excellent contrast agent due to their distinct physical attributes. This may enable the possibility of identify the stages of beta-cell loss early on. Avoiding glucose fluctuations is important while managing diabetes. Patients' treatment objectives are decided by their physicians. To determine the degree of control attained by medication and the course of diabetes, regular or daily glucose monitoring is carried out [48]. But there are drawbacks as well, such as low compliance from the patients' frequent pricking and the inability to check glucose levels at specific periods of the day (like when driving or sleeping).

Overall, the effect is erratic glucose level monitoring, which might result in hazardous variations that could exacerbate diabetes problems. Continuous glucose monitoring (CGM) devices are necessary to overcome this obstacle. For ten days, CGM was achieved via implanting biosensors under the skin (such as amperometric sensors); However, there are drawbacks to this strategy, including as instability and the requirement for weekly implantation changes [49, 50].

The aforementioned challenges in CGM can be addressed via nanomedicine. The three main parts of the glucose-sensing apparatus are the transducer, the reporter, and the detector. The

transducer transforms the measurement from the detector into an output signal. The detector measures the glucose level. At last, the reporter transforms the signal into a form that can be understood. In nanotechnology, glucose sensors are typically formed of nanoparticles, which are primarily composed of three components: glucose oxidase, glucose-binding proteins, and glucose-binding small molecules [48,55]. This allows for an accurate measurement of the glucose level. The accurate and quick detection of glucose is enabled by the connection of these nanoparticles as transducers [51]. The cornerstone of T1DM and T2DM therapy is insulin injections. Needle injections used in traditional method of delivering insulin. The idea of needles alone may be depressing, despite the fact that some needles have been greatly improved to be painless during delivery [52]. This has a major impact on patients' adherence to using insulin. Furthermore, a close plasma glucose control is not possible with the conventional subcutaneous injection due to the delay between the time of glucose measurement and insulin dosing, additionally to the difficulty in insulin absorption that results from the injection [44]. This causes fluctuations and periods of hyperglycemia. Patients and medical professionals will welcome a non-invasive method that enhances compliance and results overall.

Closed-loop microcomputer pumps or nanopumps are being created to enable timely supply of insulin while providing ongoing glucose observation, hence addressing the recent delivery issues presented by conventional techniques. Put otherwise, The way this system is designed connects the amount of insulin delivered to the level of plasma glucose. This will mitigate the chance of variations in plasma glucose levels [46,53]. It is also being investigated whether there are any other less invasive ways to give insulin orally, transdermally, or by inhalation that make use of nanoparticles [46].

5. Wound and wound dressing

Wounds classification

According to definitions, wounds are described as skin abnormalities or tissue discontinuities caused by thermal or physical trauma, as well as underlying illnesses [54]. Wounds are often classified as acute or chronic based on the type and length of the healing process [55]. The most common types of acute wounds are surgical wounds, chemical burns, mechanical wounds, and surface burns. The wound healing cycle is followed by the healing process [56,57,58].

However, Chronic injuries are ones that remain open for longer than a month and are unable to heal in a systematic manner. Although the causes of persistent wounds are diverse, they are generally associated with particular medical conditions (such diabetes). They have a terrible incidence of ulcers and are prone to bacterial infections that cause inflammation and impair wound healing [59, 60]. Patients and healthcare systems around the world are severely burdened by chronic wounds [61].



Figure 2. Classification of Wound Dressings

Nanofiber helps diabetic patients' wounds heal

An effective method for encouraging diabetic patients' wound healing is electrospun nanofibers. Diabetes frequently results in poor wound healing because of several problems, including decreased blood flow, weakened immune system, and malfunctioning growth factor signaling. Because of their special qualities, electrospun nanofibers in wound healing applications.[62, 63] The effective medication loading and release made possible by elevated ratio of surface area relative to volume of electrospun nanofibers permits the targeted and regulated delivery of therapeutic medicines to the location of the wound. Growth factors, antibiotics, and other bioactive substances able can be included in these nanofibers to promote angiogenesis, cell division, and development of extracellular matrix throughout the healing process. Furthermore, electrospun nanofibers have the ability to replicate the structure and mechanical characteristics within the extracellular matrix in its normal state, acting as a scaffold for the adherence, migration, and regeneration of cells in tissue.[64] In addition to guiding tissue regeneration and supporting cell proliferation and adhesion, the nanofiber scaffold can aid in the creation of ordered and functional tissue architectures.

Electrospun nanofibers have possess the capacity to form a barrier that shields the wound from bacteria and keeps the surrounding air wet, which promotes the wound's recovery. In addition to encouraging the elimination of wound debris and absorbing excess exudate, the nanofiber scaffold can help provide a sterile and ideal environment for wound healing. It's crucial to remember that despite the tremendous promise that electrospun nanofibers have for accelerating diabetes patients' wound healing, obstacles still require attention. These include maximizing material selection, managing therapeutic agent release kinetics, guaranteeing biocompatibility, and increasing the manufacturing of nanofiber-based wound dressings.[65,66,67]

Improve the healing process, stop infection, and produce new tissue.

Nanofibers have demonstrated significant promise in promoting tissue regeneration, averting infections, and accelerating the healing process. They are appropriate a number of biomedical applications, including wound healing because of their special qualities. First off, by offering a scaffold-like structure that resembles the ECM, or extracellular matrix of natural tissues, nanofibers can promote wound healing. By facilitating cell adhesion, migration, and proliferation, this scaffold aids in the regrowth of injured tissues. Increased cell-material interactions are made possible by the high ratio of surface area relative to volume of nanofibers, which facilitates cellular processes essential for tissue repair. Second, antimicrobial compounds can be functionalized into nanofibers to stop infections. Antimicrobial compounds can be progressively released from the nanofiber matrix, offering long-term defense against bacteria and other diseases. This regulated release mechanism lowers the danger of infection and speeds up healing by assisting in the preservation of an antibacterial environment near the location of the wound.

Moreover, growth factors, cytokines, and other bioactive substances to promote the regeneration of tissue can be delivered via nanofiber engineering. These chemicals can be placed onto the surface or enclosed inside the matrix of nanofibers, enabling a gradual and controlled release. Nanofibers possess the capacity to increase cellular activity, stimulate angiogenesis (the growth of fresh blood vessels), and speed tissue regeneration by delivering these bioactive chemicals straight to the wound site.Apart from their biological attributes, One can create nanofibers to have specific physical qualities that facilitate the healing of wounds.

For instance, aligned nanofibers can direct tissue growth and cell orientation in a manner similar to how native tissues naturally align. The regeneration of functioning tissues with better mechanical qualities may benefit from this alignment. All things considered, nanofibers provide a flexible platform that are able to tissue regeneration, stop infections, and accelerate healing. Their distinct characteristics, along with their capacity to integrate bioactive compounds and regulate release kinetics, render them a propitious instrument in the domains for wound healing and tissue engineering. There are several room for improvement in patient outcomes and medical treatment advancement with additional study and development in this field.

6. Nanofibers Electrospun for Drug Delivery:

Drug delivery methods for treatment of diabetes using electrospun nanofibers:

The capacity using electrospun nanofibers encapsulate and distribute different antidiabetic medications, such as insulin and oral hypoglycemic medicines, is one of its main benefits. [68] Electrospun nanofibers provide a great ability to load drugs and prolonged release characteristics that enable regulated and extended drug release, emulating the natural rhythm of insulin secretion. This may assist in keeping blood glucose levels at their ideal levels and lowering the frequency of medication administration. To react to variations in blood glucose levels, glucose-responsive components, such as enzymes or glucose-binding compounds, can be functionalized into electrospun nanofibers. Because of their sensitive nature, the nanofibers can release the medicine that has been encapsulated in reaction to a rise in blood glucose. This allows for a more individualized and focused approach to treating diabetes.[69] Electrospun can be applied to diabetic wound repair in individuals with diabetes in addition to drug administration. Because of lower growth factor levels and restricted blood circulation, diabetic wounds frequently show poorer healing outcomes. assist in the recovery of injuries and stop infections, growth factors or antimicrobial compounds able can be included in electrospun nanofibers. Tissue regeneration and wound closure are facilitated by the nanofiber scaffold, which offers an environment that is advantageous for the adherence, growth, and migration.

There are still issues a concept must be fixed even with the electrospun nanofibers' encouraging promise as medication delivery methods for diabetes medication.[70] These

include enhancing the synthesis of nanofibers for therapeutic applications, guaranteeing the durability of the encapsulated medications, and improving the release kinetics.

Nanofibers can decrease adverse effects, increase medicinal efficacy, and enable controlled release of therapeutic agents:

Therapeutic drugs can be precisely controlled in terms of dosage and release kinetics by using nanofibers as drug delivery devices. A benefit of nanofibers is their large ratio of volume to surface area ratio. It enables one to load and encapsulate a variety of therapeutic agents—such as nucleic acids, proteins, peptides, and tiny molecules—efficiently. There are a several ways to achieve the regulated discharge of these compounds from nanofibers, including diffusion, degradation, and stimuli-responsive activity. It's possible to build nanofibers that have particular qualities that allow for customized medication release profiles. Therapeutic agent release rate and duration, for example, can be regulated by altering the composition and structure of nanofibers. The fiber diameter, porosity, and surface chemistry can all be changed to better suit the therapeutic needs and fine-tune the release kinetics. By shielding the encapsulated therapeutic compounds from enzymatic activity and degradation, nanofibers can increase the stability and the availability the medicines. By ensuring that the therapeutic agents reach their intended target site in a functional form, this protection increases the effectiveness of the medicines.[71]

By encouraging focused distribution, nanofibers can improve therapeutic efficacy in addition to controlled release. The ability to specifically engage with target cells or tissues through the functionalization of nanofibers with ligands or targeting moieties increases the accumulation of therapeutic drugs at desired site. By minimizing off-target effects and lowering systemic toxicity, this targeted delivery strategy improves treatment outcomes. [72]Nanofibers enable focused distribution and controlled release, which reduces negative effects related to traditional medication delivery methods. Therapeutic agents with localized and prolonged release minimize medication concentration changes and potential side effects by reducing the need for frequent dosage. Furthermore, fewer healthy tissues are exposed when medications are delivered directly to the scene of the event, which lowers the possibility of adverse effects.

Numerous studies have shown how well DDS based on nanofibers may enhance medication efficacy and minimize negative effects. Anti-inflammatory drugs, for instance, have been

delivered using nanofiber scaffolds to treat chronic inflammatory illnesses, improving treatment success and minimizing systemic side effects. [73,74]

Wound healing

Wounds outcome of external laceration-induced skin trauma. Acute wounds heal faster than chronic wounds, which take longer to heal and are therefore more able to contract bacteria. The four stages of wound healing include proliferation, remodeling, inflammation, and hemostasis. Drug-loaded nanofiber scaffolds have lately piqued the interest of skin tissue engineering researchers because of their suitability for the body, flexibility, and efficient drug release [75]. These properties enable the regeneration of injured tissue. Numerous nanofiber manufacturing techniques, such as it has been possible to create forced gyration, hand spinning, rotary jet spinning, melt blowing, and electrospinning order to produce the drug-loaded nanofiber scaffolds. The prior approach to wound care was therapeutic. More effective medication release than with traditional therapy is enabled by combining drugs with polymers and spinning them into nanofibers. Until these medications were selected for their properties, such as being anti-inflammatory, antibacterial, and anti-microbial, nanofibers had an extreme degree of resistance to bacteria. Some even cause physiological changes like vasodilation [76].

most biomimetic scaffolds are made of electrospun collagen nanofibers because they promote cell growth and penetration into the formed matrix alternative to skin. In contrast to electrospun scaffolds made of single polymers, mixed poly nanofibers or hybrid poly scaffolds avoid the "fishnet effect." Because it’s unique qualities for cell adhesion and growth, chitosan-graft-poly electrospun nanofibrous mats are a good substitute for skin tissue engineering [77].

7. Nanofibers Electrospun for Tissue Engineering:

Electrospun nanofibers: their use in tissue engineering for diabetes-related complications:

In tissue engineering, electrospun nanofibers have demonstrated significant promise for treating problems associated with diabetes. These nanofibers are produced by the electrospinning method and have special qualities that enable them for applied in multiple contexts in this area.

The fabrication of tissue scaffolds regeneration is one important use. Three-dimensional structures that resemble tissues' extracellular matrix (ECM) can be produced using electrospun nanofibers. In diabetes-related disorders such diabetic ulcers or cardiovascular illnesses, these scaffolds offer a supportive environment for cell differentiation, attachment, and proliferation, supporting the regeneration of damaged tissues. To further improve their therapeutic benefits, bioactive substances like growth factors or medications can be functionalized onto electrospun nanofibers. Controlled release, is enabled by the incorporation of these bioactive chemicals within the nanofibers, enables prolonged and targeted distribution to the target spot. In diabetic patients, this method has demonstrated potential in boosting angiogenesis, wound healing, and tissue regeneration.[78] Furthermore, effective food and oxygen transfer is made possible by the high ratio of surface area to volume of electrospun nanofibers, This is necessary for preserving cell viability and function in tissue engineering constructions. Additionally, the architecture of the nanofibers enables the modification of mechanical attributes like elasticity and stiffness to better suit the needs of the target tissue.In the end, these nanofibers can help with tissue regeneration and enhance patient outcomes by acting as scaffolds, facilitating the transfer of nutrients, and allowing for the regulated discharge of bioactive chemicals.[79]

Nanofibers may be employed to build scaffolds for pancreatic tissue regeneration or blood vessel formation:

In tissue engineering, Nanofibers exhibit tremendous potential the construction of support structures for development of blood vessels and pancreatic tissue regeneration. Nanofibers are ideal for various uses because of their special qualities. Nanofiber scaffolds can offer a conducive setting for the development and differentiation of pancreatic cells with a focus on pancreatic tissue regeneration.[80] Nanofiber scaffolds have ability to stimulate cell adhesion, proliferation, and development of functional pancreatic tissue by imitating extracellular matrix (ECM) of pancreatic tissue. Specific topographical characteristics and mechanical attributes that direct cell behavior and encourage tissue regeneration able can be included in the construction of these scaffolds. Moreover, bioactive compounds that are essential for pancreatic tissue regeneration can be functionalized onto nanofibers.[79, 80] For example, to improve cell survival, proliferation, and growth factors, differentiation or signaling molecules to the nanofibers be added. The targeted and prolonged delivery of bioactive chemicals from

the nanofiber scaffolds can be facilitated by this regulated release, which will aid in regeneration of pancreatic tissue.

Nanofiber scaffolds may be applied to promote the growth of new blood vessels or to build artificial blood vessels in case of blood vessel formation. In order to encourage the creation of functioning blood vessels, the nanofiber These platforms can be constructed to have a hierarchical structure that resembles the architecture of native blood vessels. Additionally, these Scaffolds can be designed using the right mechanical characteristics and porosity to support the movement of nutrients as well as oxygen, which is necessary for the development and upkeep of blood vessels. Furthermore, surface modification of nanofibers can increase the biocompatibility of their and encourage cell attachment and development. Adding bioactive compounds or certain chemical groups that promote cell-material interactions are examples of surface alterations. They're useful tools in tissue engineering since they can replicate the matrix extracellular (ECM), release bioactive chemicals under control, and facilitate the passage of nutrients. Advancements in regenerative medicine for cardiovascular illnesses and issues connected to diabetes may result from ongoing research and development in this area.[78,79]

8. Obstacles and potential paths ahead

Current challenges and limitations in the use of nanofiber in diabetes management:

Although electrospun nanofibers have great potential for managing diabetes, their practical application will depend on resolving a number of issues and constraints.

Scalability: Because electrospinning is usually a batch process, it cannot be scaled up for large-scale manufacturing. To address the demand for widely used clinical applications, scalable production It’s essential to build processes.

Biocompatibility and degradation: When electrospun nanofibers contact live tissues, it is essential that they are biocompatible to prevent harmful reactions or deterioration. Furthermore, It’s necessary to meticulously regulate the nanofibers' rate of deterioration in order to align with the schedule for tissue regeneration.

Mechanical characteristics: In order to replicate the mechanical environment of native tissue, the mechanical characteristics of electrospun nanofibers must be tuned. It is imperative

that attain the appropriate mechanical strength, elasticity, and stability for tissue integration and functionality over the long term.

Controlled release kinetics: precise command over the disclosure release kinetics can be difficult to achieve, despite the benefits of controlled release of bioactive chemicals from nanofibers. Effective treatment requires fine-tuning the release profile to meet the therapeutic requirements.

Long-term stability: Electrospun nanofibers ought to hold onto their structural purity and performance for a huge quantity of time. Long-term success depends on ensuring their stability against environmental conditions, mechanical stress, and degradation.

Clinical translation: Regulatory and safety issues need to be considered when transitioning from laboratory from clinical uses to research. Comprehensive preclinical Clinical trials and research are required to prove the long-term advantages, protection and effectiveness of electrospun nanofibers in the handling of diabetes.

It will take multidisciplinary cooperation between researchers, engineers, doctors, and regulatory agencies to address these issues. To get over these obstacles and realize the whole application of nanofibers for diabetes management, more research and development work is required.

9. potential future developments and research directions in this field:

There are several potential future developments and research directions that hold promise for advancing sing nanofibers obtained using electrospun.

1. **Bioactive Nanofibers:** A greater variety of bioactive compounds can be included into electrospun nanofibers by researchers. This comprises signaling molecules such as growth factors and cytokines that can enhance the processes of healing and tissue regeneration. Furthermore, more exact control over therapeutic delivery may be feasible because to the growth of stimuli-responsive nanofibers, which can release bioactive chemicals in response to particular triggers like temperature or pH changes.

2. **Multifunctional Nanofibers:** It's fascinating to observe how different capabilities can be combined into a single nanofiber scaffold. For instance, adding sensors for real-time tissue parameter monitoring or mixing nanofibers with antimicrobial capabilities could help manage

diabetes-related problems even further. These multipurpose nanofibers may provide tailored and flexible therapeutic modalities.

3. **Cell-Interactive Nanofibers:** More study can be done to improve how well nanofibers and cells interact. This comprises coatings or surface alterations that encourage particular cell activities including adhesion, migration, or differentiation. Through the enhancement of the interface between cells and nanofibers, scientists can enhance the incorporation and performance of synthetic tissues.

4**. Nanofiber-Based Drug Delivery Systems:** Utilizing electrospun nanofibers, drug delivery systems can be improved. This includes creating nanofibers that can be delivered to particular tissues or cells with targeted distribution, enhanced loading capacity, and adjustable release kinetics. Therapeutics for issues associated to diabetes may be delivered precisely and locally with the assistance of such systems.

5. **In Vivo Research and Clinical Translation:** To effectively integrate electrospun nanofiber-based tissue engineering techniques into clinical practice, more thorough in vivo investigations and clinical trials must be carried out. These investigations can offer important new information about the long-term consequences, potency, and safety of nanofiber-based treatments for problems associated with diabetes.

Overall, the goals of current and upcoming research about tissue engineering with electrospun nanofibers in problems associated to diabetes are to improve patient care, improve therapy outcomes, and deepen our understanding of the fundamental mechanisms driving tissue regeneration. Technological developments and ongoing multidisciplinary collaboration will be essential for advancing this discipline.

10. Conclusion:

In conclusion, electrospun nanofibers hold tremendous promise as versatile platforms for innovative strategies in diabetes management. Through controlled engineering of fiber morphology, composition, and functionalization, these nanofibers offer tailored solutions for several aspects of diabetes care, including insulin delivery, glucose monitoring, wound, tissue, and peripheral neuropathy management. The reviewed literature demonstrates the efficacy of electrospun nanofiber-based approaches in achieving controlled drug release, enhancing biocompatibility, encouraging the regeneration of tissue, and facilitating targeted

therapy delivery. These strategies possess the capacity to address the multifaceted challenges associated with diabetes mellitus, improving patient outcomes and quality of life.

Moreover, electrospun nanofibers can mimic the extracellular matrix, providing a conducive environment for fibroblast attachment, growth, and migration, which encourages the evolution of new skin in the wound region. The permeable composition of the fiber membrane also allows for gas exchange and exudate absorption, while the surface of fiber can be easily modified to give it functionality. Electrospun nanofibers are being used for diabetic wound healing is relatively limited, nevertheless. Diabetic wound healing studies rely heavily on in vivo animal experiments, and the healing effect is mostly determined by the healing time, whereas analyses of diabetic wound healing procedure and tissue sections are limited. Additionally, the lack of research on the biocompatibility and degradability of electrospun fibers makes safety evaluations difficult.

However, several challenges and opportunities lie ahead concerning electrospun nanofibers, for diabetes management. Additional investigation is required to maximize fiber properties, refine fabrication techniques, enhance scalability, and address regulatory considerations for clinical translation. Additionally, interdisciplinary collaboration between materials scientists, biomedical engineers, clinicians, and industry partners is essential to accelerate the development and commercialization of nanofiber-based diabetes therapies. In conclusion, electrospun nanofibers offer a possible route for advancing diabetes care through innovative and patient-centric approaches. These technologies possess the ability to completely transform with further research and development to the treatment and controlling diabetic mellitus, ultimately improving the lives of millions of patients worldwide.

REFERENCES:

1. Mansoori G., Fauzi Soelaiman T. Nanotechnology—An Introduction for the Standards Community. J. ASTM Int. 2005;2:1–22. [Google Scholar]
2. Gnach A., Lipinski T., Bednarkiewicz A., Rybka J., Capobianco J.A. Upconverting nanoparticles: Assessing the toxicity. Chem. Soc. Rev. 2015;44:1561–1584. doi: 10.1039/C4CS00177J. [PubMed] [CrossRef] [Google Scholar]
3. National Nanotechnology Initiative (NNI) [(accessed on 22 July 2019)]; Available online: www.nano.gov
4. Allhoff F. On the Autonomy and Justification of Nanoethics. Nanoethics. 2007;1:185–210. doi: 10.1007/s11569-007-0018-3. [CrossRef] [Google Scholar]
5. Patra, J.K.; Gouda, S. Application of nanotechnology in textile engineering: An overview. J. Eng. Technol. Res. 2013, 5, 104–111. [Google Scholar] [CrossRef]
6. Gulrajani, M.L.; Gupta, D. Emerging techniques for functional finishing of textiles. Ind. J. Fibre Text. Res. 2011, 36, 388–397. [Google Scholar]

7. Som, C.; Gallen, E.S. NanoTextiles: Functions, Nanoparticles and Commercial Applications. 2007, pp. 1–44. Available online: https://www.empa.ch/documents/56122/328606/NanoSafeTextiles_1.pdf/b2add656-265b-42df-9196-f2768d773748 (accessed on 21 March 2021).
8. Wong, Y.W.H.; Yuen, C.W.M.; Leung, M.Y.S.; Ku, S.K.A.; Lam, H.L.I. Selected applications of nanotechnology in textiles. AUTEX Res. J. 2006, 6, 1–8. [Google Scholar]
9. Raj, S.; Jose, S.; Sumod, U.S.; Sabitha, M. Nanotechnology in cosmetics: Opportunities and challenges. J. Pharm. Bioallied Sci. 2012, 4, 186. [Google Scholar] [CrossRef]
10. Jebamalar Leavline, E.; Asir Antony Gnana Singh, D.; Prasannanayagi, S.; Kiruthika, R. A compendium of nano materials and their applications in smart nano textiles. Res. J. Nanosci. Nanotechnol. 2015, 5, 44–59. [Google Scholar] [CrossRef]
11. Xin, J.H.; Daoud, W.A.; Kong, Y.Y. A new approach to UV-blocking treatment for cotton fabrics. Text. Res. J. 2004, 74, 97–100. [Google Scholar] [CrossRef]
12. Yeo, S.Y.; Lee, H.J.; Jeong, S.H. Preparation of nanocomposite fibers for permanent antibacterial effect. J. Mater. Sci. 2003, 38, 2143–2147. [Google Scholar] [CrossRef]
13. Afifi, A.M.; Nakano, S.; Yamane, H.; Kimura, Y. Electrospinning of continuous aligning yarns with a 'Funnel' Target. Macromol. Mater. Eng. 2010, 295, 660–665. [Google Scholar] [CrossRef]
14. Pillai, C.K.S.; Sharma, C.P. Electrospinning of chitin and chitosan nanofibres. Trends Biomater. Artif. Organs 2009, 22, 179–201. [Google Scholar]
15. De Vrieze, S.; De Clerck, K. 80 years of electrospinning. In International Conference on Latest Advances in High-Tech Textiles and Textile-Based Materials; Ghent University: Ghent, Belgium, 2009; pp. 60–63. [Google Scholar]
16. Persano, L.; Camposeo, A.; Tekmen, C.; Pisignano, D. Industrial upscaling of electrospinning and applications of polymer nanofibers: A review. Macromol. Mater. Eng. 2013, 298, 504–520. [Google Scholar] [CrossRef]
17. Luo, C.J.; Stoyanov, S.D.; Stride, E.; Pelan, E.; Edirisinghe, M. Electrospinning versus fibre production methods: From specifics to technological. Chem. Soc. Rev. 2012, 41, 4708–4735. [Google Scholar] [CrossRef]
18. Nayak, R.; Padhye, R.; Kyratzis, I.L.; Truong, Y.B.; Arnold, L. Recent advances in nanofibre fabrication techniques. Text. Res. J. 2012, 82, 129–147. [Google Scholar] [CrossRef]
19. Agarwal, S.; Wendorff, J.H.; Greiner, A. Use of electrospinning technique for biomedical applications. Polymer 2008, 49, 5603–5621. [Google Scholar] [CrossRef] [Green Version]
20. Yuan, X.; Zhang, Y.; Dong, C.; Sheng, J. Morphology of ultrafine polysulfone fibers prepared by electrospinning. Polym. Int. 2004, 53, 1704–1710. [Google Scholar] [CrossRef]
21. Huang, W.; Zou, T.; Li, S.; Jing, J.; Xia, X.; Liu, X. Drug-loaded zein nanofibers prepared using a modified coaxial electrospinning process. J. Am. Assoc. Pharm. Sci. 2013, 14, 675–681. [Google Scholar] [CrossRef] [PubMed] [Green Version]
22. Pillay, V.; Dott, C.; Choonara, Y.E.; Tyagi, C.; Tomar, L.; Kumar, P.; du Toit, L.C.; Ndesendo, V.M. A review of the effect of processing variables on the fabrication of electrospun nanofibers for drug delivery applications. J. Nanomater. 2013, 2013, 1–22. [Google Scholar] [CrossRef] [Green Version]
23. Garg, K.; Bowlin, G.L. Electrospinning jets and nanofibrous structures. Biomicrofluidics 2011, 5, 013403. [Google Scholar] [CrossRef] [PubMed] [Green Version]
24. Ifegwu, O.C.; Anyakora, C. The place of electrospinning in separation science and biomedical engineering. In Electrospinning Method Used to Create Functional Nanocomposites Films; Tański, T.A., Jarka, P., Matysiak, W., Eds.; IntechOpen Limited: London, UK, 2018; p. 17. [Google Scholar]
25. Lei, T.; Peng, Q.; Chen, Q.; Xiong, J.; Sun, D. Alignment of electrospun fibers using the whipping instability. Mater. Lett. 2017, 193, 248–250. [Google Scholar] [CrossRef]
26. Xue, J.; Wu, T.; Dai, Y.; Xia, Y. Electrospinning and electrospun nanofibers: Methods, materials, and applications. Chem. Rev. 2019, 119, 5298–5415. [Google Scholar] [CrossRef]
27. Cooper, C.J.; Mohanty, A.K.; Misra, M. Electrospinning process and structure relationship of biobased poly (butylene succinate) for Nanoporous Fibers. ACS Omega 2018, 3, 5547–5557. [Google Scholar] [CrossRef]
28. Qin, X.; Subianto, S. Electrospun Nanofibers, 1st ed.; Elsevier Ltd: Cambridge, MA, USA, 2017; pp. 449–466. [Google Scholar]

29. Khan, N. Applications of electrospun nanofibers in the biomedical field. SURG J. 2012, 5, 63–73. [Google Scholar] [CrossRef]
30. Luzio, A.; Canesi, E.V.; Bertarelli, C.; Caironi, M. Electrospun polymer fibers for electronic applications. Materials 2014, 7, 906–947. [Google Scholar] [CrossRef]
31. Subbiah, T.; Bhat, G.S.; Tock, R.W.; Parameswaran, S.; Ramkumar, S.S. Electrospinning of nanofibers. J. Appl. Polym. 2005, 96, 557–569. [Google Scholar] [CrossRef]
32. Frenot, A.; Chronakis, I.S. Polymer nanofibers assembled by electrospinning. Curr. Opin. Colloid Interface Sci. 2003, 8, 64–75. [Google Scholar] [CrossRef]
33. Park, S.; Park, K.; Yoon, H.; Son, J.; Min, T.; Kim, G. Apparatus for preparing electrospun nanofibers: Designing an electrospinning process for nanofiber fabrication. Polym. Int. 2007, 56, 1361–1366. [Google Scholar] [CrossRef]
34. Ibrahim, H.M.; Klingner, A. A review on electrospun polymeric nanofibers: Production parameters and potential applications. Polym. Test. 2020, 90, 106647. [Google Scholar] [CrossRef]
35. Haider, A.; Haider, S.; Kang, I.-K. A comprehensive review summarizing the effect of electrospinning parameters and potential applications of nanofibers in biomedical and biotechnology. Arab. J. Chem. 2018, 11, 1165–1188. [Google Scholar] [CrossRef]
36. Tan, E.P.S.; Lim, C.T. Mechanical characterization of nanofibers: A review. Compos. Sci. Technol. 2006, 66, 1102–1111. [Google Scholar] [CrossRef]
37. Nisbet, D.R.; Forsythe, J.S.; Shen, W.; Finkelstein, D.I.; Horne, M.K. A review of the cellular response on electrospun Nanofibers for tissue engineering. J. Biomater. Appl. 2009, 24, 347–372. [Google Scholar] [CrossRef]
38. Kanani, A.G.; Bahram., S.H. Review on electrospun nanofibers scaffold and biomedical applications. Trends Biomater. Artif. Organs 2010, 24, 93–115. [Google Scholar]
39. Fang, J.; Niu, H.; Lin, T.; Wang, X. Applications of electrospun nanofibers. Chin. Sci. Bull. 2008, 53, 2265–2286. [Google Scholar] [CrossRef] [Green Version]
40. Thavasi, V.; Singh, G.; Ramakrishna, S. Electrospun nanofibers in energy and environmental applications. Energy Environ. Sci. 2008, 1, 205–221. [Google Scholar] [CrossRef]
41. P.Charles Poole, Jr. and Frank J. Owens, "Introduction to Nanotechnology", ISBN 0- John Wiley & Sons, Inc 2003; 07935:470-479..
42. Travis J. Sill, Horst A. von Recum, "Electrospinning: Applications in drug delivery and tissue engineering" Biomaterials 2008; 29:1989-2006
43. https://www.advancetextile.net/2020/08/what-are-nanofibers-properties-and-uses.html
44. Veiseh O., Tang B.C., Whitehead K.A., Anderson D.G., Langer R. Managing diabetes with nanomedicine: Challenges and opportunities. *Nat. Rev. Drug Discov.* 2014;14:45–57. doi: 10.1038/nrd4477. [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
45. Disanto R.M., Subramanian V., Gu Z. Recent advances in nanotechnology for diabetes treatment. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* 2015;7:548–564. doi: 10.1002/wnan.1329. [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
46. Lemmerman L.R., Das D., Higuita-Castro N., Mirmira R.G., Gallego-Perez D. Nanomedicine-Based Strategies for Diabetes: Diagnostics, Monitoring, and Treatment. *Trends Endocrinol. Metab.* 2020;31:448–458. doi: 10.1016/j.tem.2020.02.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
47. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. *Diabetes.* 2004;53((Suppl. 3)) doi: 10.2337/diabetes.53.suppl_3.S16. [PubMed] [CrossRef] [Google Scholar] [Ref list]
48. Tamborlane W., Beck R., Bode B., Buckingham B., Chase H., Clemons R., Fiallo-Scharer R., Fox L., Gilliam L., Hirsch I., et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. *N. Engl. J. Med.* 2008;359:1464–1476. doi: 10.1056/NEJMOA0805017. [PubMed] [CrossRef] [Google Scholar] [Ref list]
49. Edelman S.V., Argento N.B., Pettus J., Hirsch I.B. Clinical implications of real-time and intermittently scanned continuous glucose monitoring. *Diabetes Care.* 2018;41:2265–2274. doi: 10.2337/dc18-1150. [PubMed] [CrossRef] [Google Scholar] [Ref list]

50. Hovorka R., Nodale M., Haidar A., Wilinska M.E. Assessing performance of closed-loop insulin delivery systems by continuous glucose monitoring: Drawbacks and way forward. *Diabetes Technol. Ther.* 2013;15:4–12. doi: 10.1089/dia.2012.0185. [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
51. Scognamiglio V. Nanotechnology in glucose monitoring: Advances and challenges in the last 10 years. *Biosens. Bioelectron.* 2013;47:12–25. doi: 10.1016/j.bios.2013.02.043.
52. Grunberger G. The need for better insulin therapy. *Diabetes Obes. Metab.* 2013;15((Suppl. 1)):1–5. doi: 10.1111/dom.12061.
53. Lagopati N., Pavlatou E. Nanotechnology in Diabetes Management. *Interv. Obes. Diabetes.* 2021;5:419–424. doi: 10.31031/IOD.2021.05.000603.
54. Ather S., Harding K.G., Tate S.J. *Advanced Textiles for Wound Care.* 2nd ed. Woodhead Publishing; Cambridge, UK: 2019. Wound management and dressings; pp. 1–22. (The Textile Institute Book Series).
55. Wang W., Lu K.J., Yu C.H., Huang Q.L., Du Y.Z. Nano-drug delivery systems in wound treatment and skin regeneration. *J. Nanobiotechnology.* 2019;17:1–15. doi: 10.1186/s12951-019-0514-y.
56. Iacob A.T., Drăgan M., Ionescu O.M., Profire L., Ficai A., Andronescu E., Confederat L.G., Lupascu D. An overview of biopolymeric electrospun nanofibers based on polysaccharides for wound healing management. *Pharmaceutics.* 2020;12:1–49. doi: 10.3390/pharmaceutics12100983.
57. Tottoli E.M., Dorati R., Genta I., Chiesa E., Pisani S., Conti B. Skin wound healing process and new emerging technologies for skin wound care and regeneration. *Pharmaceutics.* 2020;12:1–30. doi: 10.3390/pharmaceutics12080735.
58. Wang Y., Feng Q., Li Z., Bai X., Wu Y., Liu Y. Evaluating the effect of integra seeded with adipose tissue-derived stem cells or fibroblasts in wound healing. *Curr. Drug Deliv.* 2020;17:629–635. doi: 10.2174/1567201817666200512104004.
59. Smet S., Probst S., Holloway S., Fourie A., Beele H., Beeckman D. The measurement properties of assessment tools for chronic wounds: A systematic review. *Int. J. Nurs. Stud.* 2021;121:103998. doi: 10.1016/j.ijnurstu.2021.103998.
60. Sen C.K. Human wounds and its burden: An updated compendium of estimates. *Adv. Wound Care.* 2019;8:39–48. doi: 10.1089/wound.2019.0946.
61. Homaeigohar S., Boccaccini A.R. Antibacterial biohybrid nanofibers for wound dressings. *Acta Biomater.* 2020;107:25–49. doi: 10.1016/j.actbio.2020.02.022.
62. Xiao L., Jia G. Modern wound dressing using polymers/biopolymers. *J. Mater. Sci. Eng.* 2018;07:7–10. doi: 10.4172/2169-0022.1000454.
63. Kuznetsova T.A., Andryukov B.G., Besednova N.N., Zaporozhets T.S., Kalinin A.V. Marine algae polysaccharides as basis for wound dressings, drug delivery, and tissue engineering: A review. *J. Mar. Sci. Eng.* 2020;8:481. doi: 10.3390/jmse8070481.
64. Fahimirad S., Ajalloueian F. Naturally-derived electrospun wound dressings for target delivery of bioactive agents. *Int. J. Pharm.* 2019;566:307–328. doi: 10.1016/j.ijpharm.2019.05.053.
65. Asanarong O., Minh Quan V., Boonrungsiman S., Sukyai P. Bioactive wound dressing using bacterial cellulose loaded with papain composite: Morphology, loading/release and antibacterial properties. *Eur. Polym. J.* 2021;143:110224. doi: 10.1016/j.eurpolymj.2020.110224.
66. Mihai M.M., Dima M.B., Dima B., Holban A.M. Nanomaterials for wound healing and infection control. *Materials.* 2019;12:2176. doi: 10.3390/ma12132176.
67. Ambekar R.S., Kandasubramanian B. Advancements in nanofibers for wound dressing: A review. *Eur. Polym. J.* 2019;117:304–336. doi: 10.1016/j.eurpolymj.2019.05.020.
68. Huang, Z.M., Zhang, Y.Z., Kotaki, M. and Ramakrishna, S. (2003) A review on polymer nanofibers by electro-spinning applications in nanocomposites, Composites Sci. Tech., 63, 2223-2253.
69. Kenawy, E.R., Bowlin, G.L., Mansfield, K., Layman, J., Simpson, D.G., Sanders, E.H., and Wnek, G.E. (2002) Release of tetracycline hydrochloride from electrospun poly (ethylene-co-vinylacetate), poly(lactic acid), and a blend, J. Control. Release, 81, 57-64
70. Yu, D.G., Shen, X.X., Branford-White, C., White, K., Zhu, L.M. and Bligh, S.W.A. (2009) Oral fast-dissolving drug delivery membranes prepared from electrospun PVP ultrafine fibers," Nanotechnology, 20, 055104.

71. Imani R., Yousefzadeh M., Nour S. Functional Nanofiber for Drug Delivery Applications BT. In: Barhoum A., Bechelany M., Makhlouf A., editors. *Handbook of Nanofibers*. Springer International Publishing; Cham, Switzerland: 2018. pp. 1–55.
72. Potrč T., Baumgartner S., Roškar R., Planinšek O., Lavrič Z., Kristl J., Kocbek P. Electrospun polycaprolactone nanofibers as a potential oromucosal delivery system for poorly water-soluble drugs. *Eur. J. Pharm. Sci.* 2015;75:101–113. doi: 10.1016/j.ejps.2015.04.004.
73. Fu A.S., von Recum H.A. *Engineering Polymer Systems for Improved Drug Delivery*. 1st ed. Wiley; New Jersey, NJ, USA: 2014. Affinity-Based Drug Delivery; pp. 429–452.
74. Karim Haidar M., Eroglu H. Nanofibers: New Insights for Drug Delivery and Tissue Engineering. *Curr. Top. Med. Chem.* 2017;17:1564–1579. doi: 10.2174/1568026616666161222102641.
75. T. Li, M. Sun, S.J.N. Wu State-Of-The-Art Review Of Electrospun Gelatin-Based Nanofiber Dressings For Wound Healing Applications
76. R.S. Ambekar, B.J.E.P.J. Kandasubramanian Advancements in nanofibers for wound dressing: A review, 117 (2019), pp. 304-336
77. L.L. Lima, *et al.* Coated electrospun bioactive wound dressings: Mechanical properties and ability to control lesion microenvironment, 100 (2019), pp. 493-504
78. T. J. Sill and H. A. von Recum, "Electrospinning: applications in drug delivery and tissue engineering," *Biomaterials*, vol. 29, no. 13, pp. 1989–2006, 2008.
79. C. T. Laurencin, A. M. A. Ambrosio, M. D. Borden, and J. A. Cooper Jr., "Tissue engineering: orthopedic applications," *Annual Review of Biomedical Engineering*, no. 1, pp. 19–46, 1999.
80. J. Lannutti, D. Reneker, T. Ma, D. Tomasko, and D. Farson, "Electrospinning for tissue engineering scaffolds," *Materials Science and Engineering C*, vol. 27, no. 3, pp. 504–509, 2007.
81. R. Murugan and S. Ramakrishna, "Design strategies of tissue engineering scaffolds with controlled fiber orientation," *Tissue Engineering*, vol. 13, no. 8, pp. 1845–1866, 2007.

	Manisha R. Mashalkar M. Pharmacy Second Year Students, Department of Pharmaceutical Quality Assurance Channabasweshwar Pharmacy College (Degree), Kava Road, Basweshwar Chowk, Latur – 413512
	Rajashri S. Biradar M. Pharmacy Second Year Students, Department of Pharmaceutical Quality Assurance Channabasweshwar Pharmacy College (Degree), Kava Road, Basweshwar Chowk, Latur – 413512

	Shivam S. Vyavahare M. Pharmacy Second Year Students, Department of Pharmaceutical Quality Assurance Channabasweshwar Pharmacy College (Degree), Kava Road, Basweshwar Chowk, Latur – 413512
	Rakhi N. Marashivane M. Pharmacy Second Year Students, Department of Pharmaceutical Quality Assurance Channabasweshwar Pharmacy College (Degree), Kava Road, Basweshwar Chowk, Latur – 413512
	Dr. Omprakash G. Bhusnure Professor & Research Director, Department of Pharmaceutical Quality Assurance, Channabasweshwar Pharmacy College (Degree), Kava Road, Basweshwar Chowk, Latur – 413512
	Pragati B. Wattamwar Assistant Professor, Department of Pharmaceutical Quality Assurance, Channabasweshwar Pharmacy College (Degree), Kava Road, Basweshwar Chowk, Latur – 413512